BiotechTube

MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cutaneous T-cell Lymphoma

Conditions

Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides

Trial Timeline

Feb 3, 2005 → Mar 13, 2006

NCT ID
NCT00091559

About MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months

MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months is a phase 2 stage product being developed by Merck for Cutaneous T-cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00091559. Target conditions include Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT00097929Phase 2Completed
NCT00091559Phase 2Completed

Competing Products

20 competing products in Cutaneous T-cell Lymphoma

See all competitors
ProductCompanyStageHype Score
ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
85
ONTAKEisaiApproved
85
E7777 9 mcg/kgEisaiPhase 3
77
ONTAKEisaiApproved
85
MogamulizumabKyowa KirinApproved
85
Mogamulizumab + Brentuximab vedotinKyowa KirinPhase 1
33
MogamulizumabKyowa KirinPhase 2
52
KW-0761 + VorinostatKyowa KirinPhase 3
77
EnzastaurinEli LillyPhase 2
52
Clopidogrel + TicagrelorAstraZenecaApproved
85
PembrolizumabMerckPhase 2
52
Comparator: vorinostatMerckPre-clinical
23
PembrolizumabMerckPhase 2
52
TR701 FAMerckPhase 2
52
PembrolizumabMerckPhase 2
52
Tulisokibart + PlaceboMerckPhase 2
52
Aspirin + Ipilimumab + PembrolizumabMerckPhase 2
52
Pembrolizumab + MogamulizumabMerckPhase 2
52
TR-701 FA + LinezolidMerckPhase 3
77
Pimasertib + DacarbazineMerckPhase 2
52

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85